The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.
Steady: 0 in the last 7 days
Updated oct 23
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Advocacy for mandatory UPF labeling challenges industry claims regarding FDA standards.1 source
Cohen critiques FDA testing standards regarding product review.1 source
- APA research informs expert critique of the institutional review process regarding GRS's status.Sub-event
Kennedy targets the FDA's GRAS loophole allowing supplements to bypass full review, with expert analysis from Harvard Medical School.1 source
Keep exploring
The entities involved
- FDA
-
Consumer Healthcare Products Association
organization
-
Calley Means
American entrepreneur (born 1985)
-
Harvard Medical School
medical school in Boston, Massachusetts
Related events
- The Dietary Supplement Health and Education Act established the regulatory framework, with FDA oversight affecting the supplement industry.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.